Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 222 articles:
HTML format
Text format



Single Articles


    December 2018
  1. JANZ S
    New wrinkle on deubiquitination in B-cell lymphoma.
    Blood. 2018;132:2529-2530.
    PubMed     Text format    


  2. MARTIN-GARCIA D, Navarro A, Valdes-Mas R, Clot G, et al
    CCND2 and CCND3 hijack immunoglobulin light chain enhancers in cyclin D1-negative mantle cell lymphoma.
    Blood. 2018 Dec 11. pii: blood-2018-07-862151. doi: 10.1182/blood-2018-07-862151
    PubMed     Text format     Abstract available


  3. MOHANTY A, Sandoval N, Phan A, Nguyen TV, et al
    Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
    Blood. 2018 Dec 10. pii: blood-2018-05-851667. doi: 10.1182/blood-2018-05-851667
    PubMed     Text format     Abstract available


  4. MENDEVILLE M, Roemer MGM, van den Hout MFCM, Los-de Vries GT, et al
    Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.
    Blood. 2018 Dec 3. pii: blood-2017-12-822171. doi: 10.1182/blood-2017-12-822171.
    PubMed     Text format    


    November 2018
  5. HUTCHINGS M
    A small change makes a big difference in Hodgkin lymphoma.
    Blood. 2018;132:2214-2215.
    PubMed     Text format    


  6. QU X, Li H, Braziel RM, Passerini V, et al
    Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016.
    Blood. 2018 Nov 16. pii: blood-2018-07-865428. doi: 10.1182/blood-2018-07-865428
    PubMed     Text format     Abstract available


  7. BRADY JL, Binkley MS, Hajj C, Chelius M, et al
    Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG.
    Blood. 2018 Nov 16. pii: blood-2018-04-843540. doi: 10.1182/blood-2018-04-843540
    PubMed     Text format     Abstract available


  8. DREYLING M, Klapper W, Rule S
    Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
    Blood. 2018 Nov 1. pii: blood-2017-08-737502. doi: 10.1182/blood-2017-08-737502.
    PubMed     Text format     Abstract available


    October 2018
  9. GRALEWSKI J, Post GR
    Cutaneous intralymphatic CD30(+) pseudolymphoma: a reactive condition mimicking lymphoma.
    Blood. 2018;132:1859.
    PubMed     Text format    


  10. KANAAN C, Burroni B
    Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma.
    Blood. 2018;132:1725.
    PubMed     Text format    


  11. DANIEL R, Chan RY
    Hyperviscosity syndrome in splenic marginal zone lymphoma.
    Blood. 2018;132:1627.
    PubMed     Text format    


  12. NASTOUPIL LJ
    Next-generation therapy for follicular lymphoma.
    Blood. 2018;132:1465-1467.
    PubMed     Text format    


  13. LEMONNIER F, Dupuis J, Sujobert P, Tournillhac O, et al
    Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.
    Blood. 2018 Oct 2. pii: blood-2018-04-840538. doi: 10.1182/blood-2018-04-840538.
    PubMed     Text format    


    September 2018
  14. MOSKOWITZ CH, Walewski J, Nademanee A, Masszi T, et al
    Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
    Blood. 2018 Sep 28. pii: blood-2018-07-861641. doi: 10.1182/blood-2018-07-861641
    PubMed     Text format     Abstract available


  15. TUN HW, Johnston PB, DeAngelis LM, Atherton PJ, et al
    Phase I study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreo-retinal lymphoma.
    Blood. 2018 Sep 27. pii: blood-2018-02-835496. doi: 10.1182/blood-2018-02-835496
    PubMed     Text format     Abstract available


  16. MOTTOK A, Wright G, Rosenwald A, Ott G, et al
    Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.
    Blood. 2018 Sep 26. pii: blood-2018-05-851154. doi: 10.1182/blood-2018-05-851154
    PubMed     Text format     Abstract available


  17. ELSHIEKH M, Naresh KN
    A rare case of renal intravascular NK/T-cell lymphoma.
    Blood. 2018;132:1354.
    PubMed     Text format    


  18. MUSILOVA K, Devan J, Cerna K, Seda V, et al
    miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
    Blood. 2018 Sep 13. pii: blood-2018-06-855502. doi: 10.1182/blood-2018-06-855502
    PubMed     Text format     Abstract available


  19. LI L, Zhang J, Chen J, Xu-Monette ZY, et al
    B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
    Blood. 2018 Sep 12. pii: blood-2018-03-841015. doi: 10.1182/blood-2018-03-841015
    PubMed     Text format     Abstract available


  20. MEHTA-SHAH N, Clemens MW, Horwitz SM
    How I treat breast implant-associated anaplastic large cell lymphoma.
    Blood. 2018 Sep 12. pii: blood-2018-03-785972. doi: 10.1182/blood-2018-03-785972
    PubMed     Text format     Abstract available


  21. KAMIJO H, Miyagaki T, Shishido-Takahashi N, Nakajima R, et al
    Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Blood. 2018 Sep 7. pii: blood-2018-04-845834. doi: 10.1182/blood-2018-04-845834.
    PubMed     Text format     Abstract available


  22. SUD A, Thomsen H, Orlando G, Forsti A, et al
    Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.
    Blood. 2018 Sep 7. pii: blood-2018-06-855296. doi: 10.1182/blood-2018-06-855296.
    PubMed     Text format     Abstract available


  23. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.
    PubMed     Text format    


  24. DIEFENBACH CS
    CART19 in Hodgkin lymphoma: are we driving the right model?
    Blood. 2018;132:982-983.
    PubMed     Text format    


  25. RUAN J, Martin P, Christos P, Cerchietti L, et al
    Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
    Blood. 2018 Sep 4. pii: blood-2018-07-859769. doi: 10.1182/blood-2018-07-859769.
    PubMed     Text format     Abstract available


    August 2018
  26. KOBE C, Goergen H, Baues C, Kuhnert G, et al
    Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
    Blood. 2018 Aug 30. pii: blood-2018-05-852129. doi: 10.1182/blood-2018-05-852129
    PubMed     Text format     Abstract available


  27. MADDOCKS K
    Update on Mantle Cell Lymphoma.
    Blood. 2018 Aug 28. pii: blood-2018-03-791392. doi: 10.1182/blood-2018-03-791392
    PubMed     Text format     Abstract available


  28. SHIMADA K, Hayakawa F, Kiyoi H
    Biology and management of primary effusion lymphoma.
    Blood. 2018 Aug 28. pii: blood-2018-03-791426. doi: 10.1182/blood-2018-03-791426
    PubMed     Text format     Abstract available


  29. TIMMERMAN J
    The run-down immunologic neighborhood in Hodgkin lymphoma.
    Blood. 2018;132:770-771.
    PubMed     Text format    


  30. HELLMUTH JC, Louissaint A Jr, Szczepanowski M, Haebe S, et al
    Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles.
    Blood. 2018 Aug 20. pii: blood-2018-03-837252. doi: 10.1182/blood-2018-03-837252
    PubMed     Text format     Abstract available


  31. PONZONI M, Campo E, Nakamura S
    INTRAVASCULAR LARGE B-CELL LYMPHOMA: A CHAMELEON WITH MULTIPLE FACES AND MANY MASKS.
    Blood. 2018 Aug 15. pii: blood-2017-04-737445. doi: 10.1182/blood-2017-04-737445
    PubMed     Text format     Abstract available


  32. DABAJA BS, Hoppe BS, Plastaras JP, Newhauser W, et al
    PROTON THERAPY FOR ADULTS WITH MEDIASTINAL LYMPHOMAS: THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) GUIDELINES.
    Blood. 2018 Aug 14. pii: blood-2018-03-837633. doi: 10.1182/blood-2018-03-837633
    PubMed     Text format     Abstract available


  33. LU X, Fernando T, Lossos C, Yusufova N, et al
    PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
    Blood. 2018 Aug 6. pii: blood-2018-02-831438. doi: 10.1182/blood-2018-02-831438.
    PubMed     Text format     Abstract available


  34. MORSCHHAUSER F, Salles G, Le Gouill S, Tilly H, et al
    An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
    PubMed     Text format     Abstract available


    July 2018
  35. EICHENAUER DA, Plutschow A, Schroder L, Fuchs M, et al
    Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Blood. 2018 Jul 31. pii: blood-2018-02-836437. doi: 10.1182/blood-2018-02-836437
    PubMed     Text format     Abstract available


  36. MARKS LJ, McCarten K, Pei Q, Friedman DL, et al
    Pericardial Effusion in Hodgkin Lymphoma: A Report from the Children's Oncology Group AHOD0031.
    Blood. 2018 Jul 30. pii: blood-2018-02-834465. doi: 10.1182/blood-2018-02-834465
    PubMed     Text format    


  37. SONG TL, Nairismagi ML, Laurensia Y, Lim JQ, et al
    Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma.
    Blood. 2018 Jul 27. pii: blood-2018-01-829424. doi: 10.1182/blood-2018-01-829424
    PubMed     Text format     Abstract available


  38. STRAUS DJ, Jung SH, Pitcher B, Kostakoglu L, et al
    CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Blood. 2018 Jul 26. pii: blood-2018-01-827246. doi: 10.1182/blood-2018-01-827246
    PubMed     Text format     Abstract available



  39. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.
    Blood. 2018;132:458-459.
    PubMed     Text format    


  40. GOLDSTEIN JS, Nastoupil LJ, Han X, Jemal A, et al
    Disparities in survival by insurance status in follicular lymphoma.
    Blood. 2018 Jul 24. pii: blood-2018-03-839035. doi: 10.1182/blood-2018-03-839035
    PubMed     Text format     Abstract available


  41. HOSER D, Schon C, Loddenkemper C, Lohneis P, et al
    Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice.
    Blood. 2018 Jul 12. pii: blood-2018-02-834036. doi: 10.1182/blood-2018-02-834036
    PubMed     Text format     Abstract available


  42. ILLERHAUS G, Schorb E, Kasenda B
    Novel agents for primary central nervous system lymphoma (PCNSL): evidence and perspectives.
    Blood. 2018 Jul 9. pii: blood-2018-01-791558. doi: 10.1182/blood-2018-01-791558.
    PubMed     Text format     Abstract available


  43. GORDON LI
    Getting to transplant in Hodgkin lymphoma: BVB.
    Blood. 2018;132:1-3.
    PubMed     Text format    


  44. GIULINO-ROTH L
    How I treat primary mediastinal B-cell lymphoma.
    Blood. 2018 Jul 5. pii: blood-2018-04-791566. doi: 10.1182/blood-2018-04-791566.
    PubMed     Text format     Abstract available


    June 2018
  45. ALRABEH R, Hao S
    "Double-expressor" intravascular large B-cell lymphoma involving the female genital tract.
    Blood. 2018;131:2993.
    PubMed     Text format    


  46. PATIL A, Manzano M, Gottwein E
    CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Blood. 2018 Jun 28. pii: blood-2018-01-828418. doi: 10.1182/blood-2018-01-828418
    PubMed     Text format     Abstract available


  47. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991
    PubMed     Text format    


  48. SVOBODA J, Rheingold SR, Gill SI, Grupp SA, et al
    Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma.
    Blood. 2018 Jun 20. pii: blood-2018-03-837609. doi: 10.1182/blood-2018-03-837609
    PubMed     Text format     Abstract available


  49. OISHI N, Brody GS, Ketterling RP, Viswanatha DS, et al
    Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.
    Blood. 2018 Jun 19. pii: blood-2017-12-821868. doi: 10.1182/blood-2017-12-821868
    PubMed     Text format    


  50. KALPADAKIS C, Pangalis GA, Sachanas S, Tsirkinidis P, et al
    Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
    Blood. 2018 Jun 18. pii: blood-2018-02-833608. doi: 10.1182/blood-2018-02-833608
    PubMed     Text format    


  51. CHOW VA, Shadman M, Gopal AK
    Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma.
    Blood. 2018 Jun 18. pii: blood-2018-04-839217. doi: 10.1182/blood-2018-04-839217
    PubMed     Text format     Abstract available


  52. FLERLAGE JE, Metzger ML, Bhakta N
    The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?
    Blood. 2018 Jun 12. pii: blood-2018-01-778548. doi: 10.1182/blood-2018-01-778548
    PubMed     Text format     Abstract available


  53. CADER FZ, Schackmann RCJ, Hu X, Wienand K, et al
    Mass cytometry of Hodgkin lymphoma reveals a CD4(+) exhausted T-effector and T-regulatory cell rich microenvironment.
    Blood. 2018 Jun 7. pii: blood-2018-04-843714. doi: 10.1182/blood-2018-04-843714.
    PubMed     Text format     Abstract available


  54. BOUDESCO C, Verhoeyen E, Martin L, Chassagne-Clement C, et al
    HSP110 sustains chronic NF-kappaB signaling in activated B cell diffuse large B cell lymphoma through MyD88 stabilization.
    Blood. 2018 Jun 5. pii: blood-2017-12-819706. doi: 10.1182/blood-2017-12-819706.
    PubMed     Text format     Abstract available


  55. ADAMS HJA, Kwee TC
    Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven.
    Blood. 2018 Jun 1. pii: blood-2018-04-845438. doi: 10.1182/blood-2018-04-845438.
    PubMed     Text format    


    May 2018
  56. NAKAYAMA S, Matsuda M
    25-Hydroxyvitamin D3-1alpha-hydroxylase- and multiple cytokine-producing diffuse large B-cell lymphoma.
    Blood. 2018;131:2271.
    PubMed     Text format    


  57. GOPAL S, Gross TG
    How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.
    Blood. 2018 May 16. pii: blood-2018-04-844472. doi: 10.1182/blood-2018-04-844472
    PubMed     Text format     Abstract available


  58. CLOT G, Jares P, Gine E, Navarro A, et al
    A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.
    Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136
    PubMed     Text format     Abstract available


  59. MANSON G, Herbaux C, Brice P, Bouabdallah K, et al
    Prolonged remissions after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
    Blood. 2018 May 3. pii: blood-2018-03-841262. doi: 10.1182/blood-2018-03-841262.
    PubMed     Text format    


  60. HU S, Wang Y
    Diffuse large B-cell lymphoma with strong aberrant expression of CD31.
    Blood. 2018;131:2090.
    PubMed     Text format    


  61. HERBAUX C, Merryman R, Devine S, Armand P, et al
    Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
    Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
    PubMed     Text format     Abstract available


  62. CERIANI L, Milan L, Martelli M, Ferreri AJM, et al
    Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
    Blood. 2018 May 2. pii: blood-2018-01-826958. doi: 10.1182/blood-2018-01-826958.
    PubMed     Text format     Abstract available


    April 2018
  63. LACASCE AS, Bociek RG, Sawas A, Caimi P, et al
    Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    Blood. 2018 Apr 27. pii: blood-2017-11-815183. doi: 10.1182/blood-2017-11-815183
    PubMed     Text format     Abstract available


  64. PHILLIPS TJ, Forero-Torres A, Sher T, Diefenbach CS, et al
    Phase 1 study of the PI3Kdelta inhibitor INCB040093 +/- JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
    Blood. 2018 Apr 25. pii: blood-2017-10-812701. doi: 10.1182/blood-2017-10-812701
    PubMed     Text format     Abstract available


  65. HIGUCHI H, Yamakawa N, Imadome KI, Yahata T, et al
    Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma.
    Blood. 2018 Apr 22. pii: blood-2017-07-794529. doi: 10.1182/blood-2017-07-794529
    PubMed     Text format     Abstract available


  66. CHUNG BM, Zieske AW
    Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index.
    Blood. 2018;131:1874.
    PubMed     Text format    


  67. BACHY E, Maurer MJ, Habermann TM, Gelas-Dore B, et al
    A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
    Blood. 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405
    PubMed     Text format     Abstract available


  68. KUPPERS R, Stevenson FK
    Critical influences on the pathogenesis of follicular lymphoma.
    Blood. 2018 Apr 17. pii: blood-2017-11-764365. doi: 10.1182/blood-2017-11-764365
    PubMed     Text format     Abstract available


  69. PASQUALUCCI L, Dalla-Favera R
    Genetics of diffuse large B cell lymphoma.
    Blood. 2018 Apr 17. pii: blood-2017-11-764332. doi: 10.1182/blood-2017-11-764332
    PubMed     Text format     Abstract available


  70. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Text format     Abstract available


  71. JETHWA A, Slabicki M, Hullein J, Jentzsch M, et al
    TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Blood. 2018 Apr 13. pii: blood-2017-09-806679. doi: 10.1182/blood-2017-09-806679
    PubMed     Text format     Abstract available


  72. TIACCI E, Ladewig E, Schiavoni G, Penson A, et al
    Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
    Blood. 2018 Apr 12. pii: blood-2017-11-814913. doi: 10.1182/blood-2017-11-814913
    PubMed     Text format     Abstract available


  73. KUBOTA Y, Kusaba K
    Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system.
    Blood. 2018;131:1765.
    PubMed     Text format    


  74. JIANG X, Zhou D
    ALK(+) small cell variant of anaplastic large cell lymphoma with leukemic presentation.
    Blood. 2018;131:1764.
    PubMed     Text format    


  75. WHITESIDE TL
    Lymphoma exosomes reprogram the bone marrow.
    Blood. 2018;131:1635-1636.
    PubMed     Text format    


  76. STELLING A, Hashwah H, Bertram K, Manz MG, et al
    The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.
    Blood. 2018 Apr 3. pii: blood-2017-10-810630. doi: 10.1182/blood-2017-10-810630.
    PubMed     Text format     Abstract available


    March 2018
  77. YAMAGUCHI M, Suzuki R, Oguchi M
    Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Blood. 2018 Mar 30. pii: blood-2017-12-791418. doi: 10.1182/blood-2017-12-791418
    PubMed     Text format     Abstract available


  78. BATTISTELLO E, Katanayeva N, Dheilly E, Tavernari D, et al
    Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
    Blood. 2018 Mar 22. pii: blood-2017-10-809210. doi: 10.1182/blood-2017-10-809210
    PubMed     Text format     Abstract available


  79. COTTEREAU AS, Versari A, Luminari S, Dupuis J, et al
    Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
    Blood. 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
    PubMed     Text format     Abstract available


  80. WANG HY, Jaffe ES
    An anaplastic T-cell lymphoma mimicking classical Hodgkin lymphoma.
    Blood. 2018;131:1262.
    PubMed     Text format    


  81. BRICE P
    Refractory Hodgkin lymphoma: time for targeted therapies?
    Blood. 2018;131:1156-1157.
    PubMed     Text format    


  82. REN W, Ye X, Su H, Li W, et al
    Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.
    Blood. 2018 Mar 15. pii: blood-2017-11-817601. doi: 10.1182/blood-2017-11-817601
    PubMed     Text format     Abstract available


  83. SCHRADER AMR, Jansen PM, Willemze R, Vermeer MH, et al
    High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
    Blood. 2018 Mar 7. pii: blood-2017-12-822817. doi: 10.1182/blood-2017-12-822817.
    PubMed     Text format    


  84. MOTTOK A, Steidl C
    Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.
    Blood. 2018 Mar 2. pii: blood-2017-09-772632. doi: 10.1182/blood-2017-09-772632.
    PubMed     Text format     Abstract available


  85. BROCKELMANN PJ, Sasse S, Engert A
    Early-stage classical Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-10-772665. doi: 10.1182/blood-2017-10-772665.
    PubMed     Text format     Abstract available


  86. LIM SH, Johnson PWM
    Optimizing therapy in advanced stage Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-09-772640. doi: 10.1182/blood-2017-09-772640.
    PubMed     Text format     Abstract available


  87. SEHN LH
    Introduction to a review series on Hodgkin Lymphoma: Change is here.
    Blood. 2018 Mar 2. pii: blood-2018-02-824045. doi: 10.1182/blood-2018-02-824045.
    PubMed     Text format    


  88. MEHTA-SHAH N, Bartlett NL
    Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
    Blood. 2018 Mar 2. pii: blood-2017-09-772681. doi: 10.1182/blood-2017-09-772681.
    PubMed     Text format     Abstract available


  89. SHAH GL, Moskowitz CH
    Transplant strategies in relapsed/refractory Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-09-772673. doi: 10.1182/blood-2017-09-772673.
    PubMed     Text format     Abstract available



  90. Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017;130(20):2180-2185.
    Blood. 2018;131:1037.
    PubMed     Text format    


    February 2018
  91. SCOTT DW, King RL, Staiger AM, Ben-Neriah S, et al
    High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
    Blood. 2018 Feb 23. pii: blood-2017-12-820605. doi: 10.1182/blood-2017-12-820605
    PubMed     Text format     Abstract available


  92. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.
    PubMed     Text format    


  93. VIGANO E, Gunawardana J, Mottok A, Van Tol T, et al
    Somatic IL4R Mutations in Primary Mediastinal Large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.
    Blood. 2018 Feb 21. pii: blood-2017-09-808907. doi: 10.1182/blood-2017-09-808907
    PubMed     Text format     Abstract available


  94. VARI F, Arpon D, Keane C, Hertzberg MS, et al
    Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
    Blood. 2018 Feb 15. pii: blood-2017-07-796342. doi: 10.1182/blood-2017-07-796342
    PubMed     Text format     Abstract available


  95. SPINA V, Bruscaggin A, Cuccaro A, Martini M, et al
    Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma.
    Blood. 2018 Feb 15. pii: blood-2017-11-812073. doi: 10.1182/blood-2017-11-812073
    PubMed     Text format     Abstract available



  96. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
    Blood. 2018;131:587-588.
    PubMed     Text format    


  97. COTTEREAU AS, Versari A, Loft A, Casasnovas O, et al
    Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial.
    Blood. 2018 Feb 1. pii: blood-2017-07-795476. doi: 10.1182/blood-2017-07-795476.
    PubMed     Text format     Abstract available


  98. JIANG W, Zhou X, Li Z, Liu K, et al
    Prolyl 4-Hydroxylase 2 Promotes B-cell Lymphoma Progression via Hydroxylation of Carabin.
    Blood. 2018 Feb 1. pii: blood-2017-07-794875. doi: 10.1182/blood-2017-07-794875.
    PubMed     Text format     Abstract available


    January 2018
  99. VOSE JM
    Peripheral T-cell lymphoma: novel backbone.
    Blood. 2018;131:375-376.
    PubMed     Text format    


  100. ZIJLSTRA JM, Boellaard R
    Baseline PET as prognostic marker for Hodgkin?
    Blood. 2018;131:3-4.
    PubMed     Text format    


  101. XU-MONETTE ZY, Zhou J, Young KH
    PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Blood. 2018;131:68-83.
    PubMed     Text format     Abstract available


  102. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Text format     Abstract available


    December 2017
  103. BATTISTELLA M, Leboeuf C, Ram-Wolff C, Hurabielle C, et al
    KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Blood. 2017;130:2900-2902.
    PubMed     Text format    


  104. FRIEDBERG JW, Forero-Torres A, Bordoni RE, Cline VJM, et al
    Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL.
    Blood. 2017;130:2829-2837.
    PubMed     Text format     Abstract available


  105. ZINZANI PL
    ALCL: is it now a curable disease?
    Blood. 2017;130:2691-2692.
    PubMed     Text format    


  106. HORWITZ SM, Koch R, Porcu P, Oki Y, et al
    Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.
    Blood. 2017 Dec 12. pii: blood-2017-08-802470. doi: 10.1182/blood-2017-08-802470
    PubMed     Text format     Abstract available


  107. HERRERA AF, Moskowitz AJ, Bartlett NL, Vose JM, et al
    Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2017 Dec 11. pii: blood-2017-10-811224. doi: 10.1182/blood-2017-10-811224
    PubMed     Text format     Abstract available


    November 2017
  108. STEIDL C
    The ecosystem of classical Hodgkin lymphoma.
    Blood. 2017;130:2360-2361.
    PubMed     Text format    


  109. KOHNKEN R, Wen J, Mundy-Bosse B, McConnell K, et al
    Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Blood. 2017 Nov 27. pii: blood-2017-09-805663. doi: 10.1182/blood-2017-09-805663
    PubMed     Text format     Abstract available


  110. LIU WR, Shipp MA
    Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Blood. 2017;130:2265-2270.
    PubMed     Text format     Abstract available


  111. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.
    PubMed     Text format    


  112. GREEN MR
    Chromatin modifying gene mutations in follicular lymphoma.
    Blood. 2017 Nov 20. pii: blood-2017-08-737361. doi: 10.1182/blood-2017-08-737361
    PubMed     Text format     Abstract available



  113. Diffuse large B-cell lymphoma in the elderly.
    Blood. 2017;130:2235.
    PubMed     Text format    


  114. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  115. GALLAMINI A
    Relapsed/refractory HL: FDG-PET is the trump card.
    Blood. 2017;130:2154-2155.
    PubMed     Text format    


  116. AMENGUAL JE, Lichtenstein R, Lue J, Sawas A, et al
    A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Blood. 2017 Nov 15. pii: blood-2017-09-806737. doi: 10.1182/blood-2017-09-806737
    PubMed     Text format     Abstract available


  117. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  118. MOTTOK A, Jurinovic V, Farinha P, Rosenwald A, et al
    FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens.
    Blood. 2017 Nov 9. pii: blood-2017-08-799080. doi: 10.1182/blood-2017-08-799080.
    PubMed     Text format     Abstract available


  119. RYAN MC, Palanca-Wessels MC, Schimpf B, Gordon KA, et al
    Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
    Blood. 2017;130:2018-2026.
    PubMed     Text format     Abstract available


    October 2017
  120. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  121. FISH K, Sora RP, Schaller SJ, Longnecker R, et al
    EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Blood. 2017 Oct 26. pii: blood-2017-07-796821. doi: 10.1182/blood-2017-07-796821
    PubMed     Text format     Abstract available


  122. BARTLETT NL, Costello BA, LaPlant BR, Ansell SM, et al
    Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial.
    Blood. 2017 Oct 26. pii: blood-2017-09-804641. doi: 10.1182/blood-2017-09-804641
    PubMed     Text format     Abstract available


  123. LAMY T, Damaj G, Soubeyran P, Gyan E, et al
    R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL).
    Blood. 2017 Oct 23. pii: blood-2017-07-793984. doi: 10.1182/blood-2017-07-793984
    PubMed     Text format     Abstract available



  124. Genomic analysis of adult Burkitt lymphoma.
    Blood. 2017;130:1871.
    PubMed     Text format    


  125. PILERI SA
    Understanding lymphoma molecular complexity.
    Blood. 2017;130:1780-1781.
    PubMed     Text format    


  126. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  127. AKHTARI M, Milgrom SA, Pinnix CC, Reddy JP, et al
    Re-classifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
    Blood. 2017 Oct 16. pii: blood-2017-04-773838. doi: 10.1182/blood-2017-04-773838
    PubMed     Text format     Abstract available


  128. BALAKRISHNA JP, Jaffe ES
    Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma.
    Blood. 2017;130:1683.
    PubMed     Text format    


  129. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  130. PRO B, Advani R, Brice P, Bartlett NL, et al
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
    Blood. 2017 Oct 3. pii: blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049.
    PubMed     Text format     Abstract available


  131. CYRENNE BM, Lewis J, Weed J, Carlson K, et al
    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood. 2017 Oct 2. pii: blood-2017-06-792150. doi: 10.1182/blood-2017-06-792150.
    PubMed     Text format     Abstract available


    September 2017

  132. MALT lymphoma prognostic index.
    Blood. 2017;130:1486.
    PubMed     Text format    


  133. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  134. PARK J, Yang J, Wenzel AT, Ramachandran A, et al
    Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
    Blood. 2017;130:1430-1440.
    PubMed     Text format     Abstract available


  135. MISHRA A, Porcu P
    Expanding and expounding the genomic map of CTCL.
    Blood. 2017;130:1389-1390.
    PubMed     Text format    


  136. ROELENS M, Delord M, Ram-Wolff C, Marie-Cardine A, et al
    Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity.
    Blood. 2017;130:1468-1471.
    PubMed     Text format    


  137. MALEK A, Bhagat G
    Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression.
    Blood. 2017;130:1388.
    PubMed     Text format    


  138. STEPHENS DM
    Brentuximab: is it time for a new "B" in ABVD?
    Blood. 2017;130:1281-1282.
    PubMed     Text format    


  139. HERTZBERG M
    High-risk DLBCL: interim PET? Not yet.
    Blood. 2017;130:1277-1278.
    PubMed     Text format    


  140. MARTIN P, Ruan J, Leonard JP
    The potential for chemotherapy-free strategies in mantle cell lymphoma.
    Blood. 2017 Sep 12. pii: blood-2017-05-737510. doi: 10.1182/blood-2017-05-737510
    PubMed     Text format     Abstract available


  141. CAREY CD, Gusenleitner D, Lipschitz M, Roemer MGM, et al
    Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Blood. 2017 Sep 11. pii: blood-2017-03-770719. doi: 10.1182/blood-2017-03-770719
    PubMed     Text format     Abstract available


  142. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  143. TESSON B, Huet S, Grange B, Jallades L, et al
    Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes.
    Blood. 2017;130:1267-1269.
    PubMed     Text format    


  144. MOSKOWITZ AJ, Schoder H, Gavane S, Thoren KL, et al
    Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877.
    PubMed     Text format     Abstract available


    August 2017
  145. KHODARAHMI I, Ghesani N
    Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Blood. 2017;130:1174.
    PubMed     Text format    


  146. DAVIDS MS
    Targeting BCL-2 in B-cell lymphomas.
    Blood. 2017;130:1081-1088.
    PubMed     Text format     Abstract available


  147. KREMER KN, Dinkel BA, Sterner RM, Osborne DG, et al
    TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.
    Blood. 2017;130:982-994.
    PubMed     Text format     Abstract available


  148. ESKELUND CW, Dahl C, Hansen JW, Westman M, et al
    TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
    Blood. 2017 Aug 17. pii: blood-2017-04-779736. doi: 10.1182/blood-2017-04-779736
    PubMed     Text format     Abstract available


  149. LIN RJ, Behera M, Diefenbach CS, Flowers CR, et al
    The Role of Anthracycline and Comprehensive Geriatric Assessment for Elderly Patients with Diffuse Large B-cell Lymphoma.
    Blood. 2017 Aug 16. pii: blood-2017-05-736975. doi: 10.1182/blood-2017-05-736975
    PubMed     Text format    


  150. BOUSKA A, Bi C, Lone W, Zhang W, et al
    Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
    Blood. 2017 Aug 11. pii: blood-2017-02-767335. doi: 10.1182/blood-2017-02-767335
    PubMed     Text format     Abstract available


  151. SALAR A, Domingo-Domenech E, Panizo C, Nicolas C, et al
    Long-term results of a phase II study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
    Blood. 2017 Aug 11. pii: blood-2017-07-795302. doi: 10.1182/blood-2017-07-795302
    PubMed     Text format    


  152. OKONKWO L, Jaffe ES
    Intravascular large cell lymphoma of NK/T-cell type, EBV positive.
    Blood. 2017;130:837.
    PubMed     Text format    


  153. NAM AS, Tam W
    An intrasinusoidal extracavitary variant of primary effusion lymphoma.
    Blood. 2017;130:836.
    PubMed     Text format    


  154. WEIGERT O, Weinstock DM
    The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
    Blood. 2017 Aug 7. pii: blood-2017-07-737353. doi: 10.1182/blood-2017-07-737353.
    PubMed     Text format     Abstract available


  155. CRUMP M, Neelapu SS, Farooq U, Van Den Neste E, et al
    Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
    Blood. 2017 Aug 3. pii: blood-2017-03-769620. doi: 10.1182/blood-2017-03-769620.
    PubMed     Text format     Abstract available


  156. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  157. TSUYAMA N, Sakata S, Baba S, Mishima Y, et al
    BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
    Blood. 2017;130:489-500.
    PubMed     Text format     Abstract available


  158. DOMINGUEZ-SOLA D
    SOX11 holds mantle cell lymphoma's key to home.
    Blood. 2017;130:389-391.
    PubMed     Text format    


  159. EICHENAUER DA, Engert A
    R-CHOP in NLPHL: who should receive it?
    Blood. 2017;130:387-388.
    PubMed     Text format    


  160. COURTOIS L, Sujobert P
    Morphologic features of mu-heavy-chain disease.
    Blood. 2017;130:558.
    PubMed     Text format    


  161. CONNORS JM, Ansell SM, Fanale M, Park SI, et al
    Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma.
    Blood. 2017 Jul 21. pii: blood-2017-05-784678. doi: 10.1182/blood-2017-05-784678
    PubMed     Text format    



  162. Predicting transformation of follicular lymphoma.
    Blood. 2017;130:383.
    PubMed     Text format    


  163. GONG S, Hijiya N
    Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination.
    Blood. 2017;130:381.
    PubMed     Text format    


  164. FEHNIGER TA
    CD70 turns on NK cells to attack lymphoma.
    Blood. 2017;130:238-239.
    PubMed     Text format    


  165. CABANILLAS F, Rivera N
    Check this checkpoint inhibitor in lymphoma.
    Blood. 2017;130:234-235.
    PubMed     Text format    


  166. ERDMANN T, Klener P, Lynch JT, Grau M, et al
    Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Blood. 2017;130:310-322.
    PubMed     Text format     Abstract available


  167. THIEBLEMONT C, Cascione L, Conconi A, Kiesewetter B, et al
    A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial.
    Blood. 2017 Jul 18. pii: blood-2017-03-771915. doi: 10.1182/blood-2017-03-771915
    PubMed     Text format     Abstract available


  168. WOODS DM, Woan KV, Cheng F, Sodre AL, et al
    T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.
    Blood. 2017;130:146-155.
    PubMed     Text format     Abstract available


  169. CASASNOVAS RO, Ysebaert L, Thieblemont C, Bachy E, et al
    A FDG-PET driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase II study.
    Blood. 2017 Jul 12. pii: blood-2017-02-766691. doi: 10.1182/blood-2017-02-766691
    PubMed     Text format     Abstract available


  170. SZYDLOWSKI M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, et al
    Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Blood. 2017 Jul 11. pii: blood-2017-01-760702. doi: 10.1182/blood-2017-01-760702
    PubMed     Text format     Abstract available


    June 2017
  171. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    


  172. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  173. HAVRANEK O, Xu J, Kohrer S, Wang Z, et al
    Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-10-747303. doi: 10.1182/blood-2016-10-747303
    PubMed     Text format     Abstract available


  174. CHIN CK, Cheah CY
    How I treat patients with aggressive lymphoma at high risk of CNS relapse.
    Blood. 2017 Jun 13. pii: blood-2017-03-737460. doi: 10.1182/blood-2017-03-737460
    PubMed     Text format     Abstract available


  175. FRIEDBERG JW
    How I treat "Double Hit" lymphoma.
    Blood. 2017 Jun 9. pii: blood-2017-04-737320. doi: 10.1182/blood-2017-04-737320.
    PubMed     Text format     Abstract available


  176. CHRISTIAN B
    Checkpoint inhibition in CNS lymphoma.
    Blood. 2017;129:3045-3046.
    PubMed     Text format    


  177. ZHANG H, Chen Z, Miranda RN, Medeiros LJ, et al
    Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
    Blood. 2017 Jun 7. pii: blood-2017-02-767293. doi: 10.1182/blood-2017-02-767293.
    PubMed     Text format     Abstract available


    May 2017
  178. GILL K
    CD5-negative mantle cell lymphoma of the breast.
    Blood. 2017;129:2950.
    PubMed     Text format    


  179. SCHMIDT J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, et al
    Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.
    Blood. 2017 May 22. pii: blood-2017-03-776278. doi: 10.1182/blood-2017-03-776278
    PubMed     Text format     Abstract available


  180. BALSAS P, Palomero J, Eguileor A, Rodriguez ML, et al
    SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
    Blood. 2017 May 22. pii: blood-2017-04-776740. doi: 10.1182/blood-2017-04-776740
    PubMed     Text format     Abstract available


  181. FANALE MA, Cheah CY, Rich A, Medeiros LJ, et al
    Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Blood. 2017 May 18. pii: blood-2017-02-766121. doi: 10.1182/blood-2017-02-766121
    PubMed     Text format     Abstract available


  182. PEDERSEN MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, et al
    DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.
    Blood. 2017 May 18. pii: blood-2016-12-755496. doi: 10.1182/blood-2016-12-755496
    PubMed     Text format    


  183. GAY C, Delarue R, Milpied N, Oberic L, et al
    Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.
    Blood. 2017;129:2811-2813.
    PubMed     Text format    


  184. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  185. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  186. TOUT M, Casasnovas O, Meignan M, Lamy T, et al
    Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
    Blood. 2017;129:2616-2623.
    PubMed     Text format     Abstract available


  187. ZINZANI PL, Ribrag V, Moskowitz CH, Michot JM, et al
    Safety & tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
    Blood. 2017 May 10. pii: blood-2016-12-758383. doi: 10.1182/blood-2016-12-758383
    PubMed     Text format     Abstract available


  188. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  189. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  190. HAVERKOS BM, Abbott D, Hamadani M, Armand P, et al
    PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346.
    PubMed     Text format     Abstract available


  191. KURUVILLA J, Savona M, Baz R, Mau-Sorensen M, et al
    Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma.
    Blood. 2017 May 3. pii: blood-2016-11-750174. doi: 10.1182/blood-2016-11-750174.
    PubMed     Text format     Abstract available


    April 2017
  192. JACCARD A, Hermine O
    A major turning point in NK/T-cell lymphoma?
    Blood. 2017;129:2342-2343.
    PubMed     Text format    


  193. BUJISIC B, De Gassart A, Tallant R, Demaria O, et al
    Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Blood. 2017;129:2420-2428.
    PubMed     Text format     Abstract available


  194. CHIECCHIO L, Cullis JO
    De novo Richter transformation.
    Blood. 2017;129:2455.
    PubMed     Text format    



  195. Risk of heart failure following Hodgkin lymphoma.
    Blood. 2017;129:2334.
    PubMed     Text format    


  196. BHATT S, Parvin S, Zhang Y, Cho HM, et al
    Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Blood. 2017;129:2246-2256.
    PubMed     Text format     Abstract available


  197. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  198. LE GOUILL S, Casasnovas RO
    Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?
    Blood. 2017 Apr 17. pii: blood-2016-05-672196. doi: 10.1182/blood-2016-05-672196
    PubMed     Text format     Abstract available


  199. KRIDEL R, Sehn LH, Gascoyne RD
    Can histologic transformation of follicular lymphoma be predicted and prevented?
    Blood. 2017 Apr 13. pii: blood-2017-03-691345. doi: 10.1182/blood-2017-03-691345
    PubMed     Text format     Abstract available


  200. MILLER HK, Santo L, Camargo MC, Winkler CA, et al
    Coxiella burnetii antibody seropositivity is not a risk factor for AIDS-related non-Hodgkin lymphoma.
    Blood. 2017 Apr 10. pii: blood-2016-12-756569. doi: 10.1182/blood-2016-12-756569
    PubMed     Text format    


  201. KAKKASSERY V, Schroers R, Coupland SE, Wunderlich MI, et al
    Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma.
    Blood. 2017 Apr 7. pii: blood-2017-01-765180. doi: 10.1182/blood-2017-01-765180.
    PubMed     Text format    


    March 2017
  202. KAWASAKI K, Karube K
    Peripheral T-cell lymphoma with EBV-infected "anaplastic" B-cell proliferation confined to sinuses.
    Blood. 2017;129:1885.
    PubMed     Text format    


  203. ALINARI L
    Toward autophagy-targeted therapy in lymphoma.
    Blood. 2017;129:1740-1742.
    PubMed     Text format    


  204. NAYAK L, Iwamoto FM, LaCasce A, Mukundan S, et al
    PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Blood. 2017 Mar 29. pii: blood-2017-01-764209. doi: 10.1182/blood-2017-01-764209
    PubMed     Text format     Abstract available


  205. ENNISHI D, Mottok A, Ben-Neriah S, Shulha HP, et al
    Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact.
    Blood. 2017 Mar 28. pii: blood-2016-11-747022. doi: 10.1182/blood-2016-11-747022
    PubMed     Text format     Abstract available


  206. GOPAL AK, Kahl BS, Flowers CR, Martin P, et al
    Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Blood. 2017 Mar 21. pii: blood-2016-12-757740. doi: 10.1182/blood-2016-12-757740
    PubMed     Text format    


  207. JAHN L, Hombrink P, Hagedoorn RS, Kester MG, et al
    TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
    Blood. 2017;129:1284-1295.
    PubMed     Text format     Abstract available


  208. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    


    February 2017
  209. CHONG EA, Melenhorst JJ, Lacey SF, Ambrose DE, et al
    PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
    Blood. 2017;129:1039-1041.
    PubMed     Text format    


  210. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


    January 2017
  211. ABRAMSON JS
    Recurrent mutations and targeted therapy in FL.
    Blood. 2017;129:402-403.
    PubMed     Text format    


  212. SESQUES P, Johnson NA
    Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Blood. 2017;129:280-288.
    PubMed     Text format     Abstract available


  213. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  214. YAHALOM J
    Curative radiation for orbital MZL: how much?
    Blood. 2017;129:270-271.
    PubMed     Text format    


  215. KUO SH, Chen LT, Lin CW, Yeh KH, et al
    Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.
    Blood. 2017;129:188-198.
    PubMed     Text format     Abstract available


  216. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.
    PubMed     Text format    


  217. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.
    PubMed     Text format    


  218. STEIDL C
    Exposing Hodgkin-Reed-Sternberg cells.
    Blood. 2017;129:6-7.
    PubMed     Text format    


    December 2016
  219. HUANG Q
    A striking bone marrow dyserythropoietic change but no anemia.
    Blood. 2016;128:3177.
    PubMed     Text format    


  220. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Text format     Abstract available


    November 2016
  221. VILLA D
    Novel antivirals for HCV-associated lymphomas.
    Blood. 2016;128:2482-2483.
    PubMed     Text format    


    September 2016
  222. ARCAINI L, Besson C, Frigeni M, Fontaine H, et al
    Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Blood. 2016 Sep 7. pii: blood-2016-05-714667.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: